NEURO NEWS
Neurological News with information about conditions, treatments, current studies and breakthroughs.
TMS Therapy at Countryside Neurology – Long-Term Depression Relief
Unlocking New Horizons in Depression Treatment In a groundbreaking clinical trial named BRIGhTMIND, the University of Nottingham reveals a significant [...]
Revolutionizing Depression Treatment: TMS Therapy at Countryside Neurology
Revolutionizing Depression Treatment In a major leap forward, researchers from the University of Nottingham conducted a significant clinical trial employing [...]
Happy Valentine’s Day from Countryside Neurology!
Countryside Neurology wishes everyone a heartwarming and joy-filled Valentine's Day! 💖 May your day be filled with love, connection, and [...]
Revolutionizing Mental Health: Accelerated Relief from Depression with TMS Therapy
In the realm of mental health breakthroughs, the unconventional yet effective transcranial magnetic stimulation (TMS) is making waves. This FDA-approved, [...]
Transformative Mental Health: Accelerated TMS Therapy for Post-COVID Well-being
Embark on a compelling journey within a transformative case study, revealing the profound impact of accelerated bilateral theta-burst transcranial magnetic [...]
Balancing Work and Self-Care During TMS Therapy: A Guide from Countryside Neurology
Navigating the delicate balance between work responsibilities and self-care during the transformative journey of Transcranial Magnetic Stimulation (TMS) therapy at [...]
- Medicinal Signaling Cell Therapy Fast Tracked for Mild Alzheimer Disease July 29, 2024The investigational allogeneic cellular therapy is believed to impart anti-inflammatory, pro-vascular, and pro-regenerative effects.
- Endo Recalls Clonazepam ODT Due to Carton Label Displaying Incorrect Strength July 29, 2024The product is being recalled because the incorrect strength of 0.125mg is appearing on the carton labels.
- Investigational Gene Therapy for Parkinson Disease Gets Fast Track Status July 22, 2024AB-1005 is an investigational gene therapy based on AAV2 containing the human GDNF transgene.
- FDA Approves Aflibercept Biosimilar Ahzantive July 16, 2024Ahzantive is a vascular endothelial growth factor inhibitor.
- Ketamine May Reduce Cluster Headache Symptoms July 2, 2024Researchers sought to evaluate ketamine as a potentially promising treatment approach.
Get Social